Research Links Pancreatic Cancer Survival Rates With Arrangement Of Immune Cells In Tumors Facing The Cancer Revolution podcast

Research links pancreatic cancer survival rates with arrangement of immune cells in tumors

2y ago 37:37

内容由The Cancer Revolution提供。所有播客内容（包括剧集、图形和播客描述）均由 The Cancer Revolution 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

In this episode of Facing the Cancer Revolution Podcast we discuss pancreatic cancer to stop prostate cancers and exocrine cancers. We discuss breakthough research, improvements in available treatments.

Pancreatic cancer is frequently diagnosed at an advanced stage, which makes it difficult to treat. It remains relatively rare (about 3% of cancers), but one of the most feared. When possible, pancreatic cancer is treated with surgical measures combined with stem cells and chemotherapy treatment. Non-operable cancers are treated with chemotherapy, possibly supplemented by immunotherapy.

Because they remain symptomless for a long time, pancreatic cancers are diagnosed at a late stage in 80 to 90% of cases. Their treatment is therefore often difficult. They remain rare, representing approximately 3% of cancers. In France, between 8 and 10,000 new cases of pancreatic cancer are diagnosed each year, causing about as many deaths. Pancreatic cancer is slightly more common in men. The average age at diagnosis is 75 years in men and 80 years in women.

In 90% of cases, pancreatic cancer develops from cells that line the ducts leading pancreatic juice to the intestine (see box): this is ductal adenocarcinoma of the pancreas. Most often (70 to 80% of cases), this cancer is born in the part of the pancreas which is close to the small intestine (the "head" of the pancreas).

Resources Discussed in Podcast

Links to Previous Shows